Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gramatzki

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Blood|May 1, 1996
HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factorD Elsässer, T Valerius, R Repp, et al.
Bone Marrow Transplantation|October 3, 2020
Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMTJ Loke, M Labopin, C Craddock, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 9, 2000
Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapyB Stockmeyer, M Dechant, M van Egmond, et al.
Cancer Research|July 29, 1998
Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cellsD Würflein, M Dechant, B Stockmeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II studyW Brugger, J Hirsch, F Grünebach, et al.
Scandinavian Journal of Immunology|July 15, 2017
CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma CellsM Peipp, D Wesch, H-H Oberg, et al.
Blood|December 31, 1997
FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapyT Valerius, B Stockmeyer, A B van Spriel, et al.
Medizinische Klinik (Munich, Germany : 1983)|April 12, 1996
[Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group]G Hübner, H Link, P Schönrock-Nabulsi, et al.
British Journal of Cancer|December 17, 2003
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancerR Repp, H H van Ojik, T Valerius, et al.
Leukemia|June 5, 2012
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cellsP Glorius, A Baerenwaldt, C Kellner, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Blood|May 1, 1996
HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factorD Elsässer, T Valerius, R Repp, et al.
Bone Marrow Transplantation|October 3, 2020
Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMTJ Loke, M Labopin, C Craddock, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 9, 2000
Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapyB Stockmeyer, M Dechant, M van Egmond, et al.
Cancer Research|July 29, 1998
Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cellsD Würflein, M Dechant, B Stockmeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II studyW Brugger, J Hirsch, F Grünebach, et al.
Scandinavian Journal of Immunology|July 15, 2017
CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma CellsM Peipp, D Wesch, H-H Oberg, et al.
Blood|December 31, 1997
FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapyT Valerius, B Stockmeyer, A B van Spriel, et al.
Medizinische Klinik (Munich, Germany : 1983)|April 12, 1996
[Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group]G Hübner, H Link, P Schönrock-Nabulsi, et al.
British Journal of Cancer|December 17, 2003
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancerR Repp, H H van Ojik, T Valerius, et al.
Leukemia|June 5, 2012
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cellsP Glorius, A Baerenwaldt, C Kellner, et al.
Pageof 9